A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma

Secondary

• Overall survival (OS)

  Time frame: Up to 5 years after the last participant is randomized

• Overall response rate (ORR)

  Time frame: Up to 5 years after the last participant is randomized

• Minimal residual disease (MRD)-negative status

  Time frame: Up to 5 years after the last participant is randomized

• Complete response rate (CRR)

  Time frame: Up to 5 years after the last participant is randomized

• Time to response (TTR)

  Time frame: Up to 5 years after the last participant is randomized

• Duration of response (DOR)

  Time frame: Up to 5 years after the last participant is randomized

• Maximum observed concentration (Cmax) of transgene level

  Time frame: Up to 5 years after the last participant is randomized

• Time of maximum observed plasma concentration (Tmax) of transgene level

  Time frame: Up to 5 years after the last participant is randomized

• Area under the concentration-time curve (AUC) of transgene level

  Time frame: Up to 5 years after the last participant is randomized

• Changes from baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire- Core 30 items (QLQ-C30) primary domains

  Time frame: Up to 5 years after the last participant is randomized

• Changes from baseline in EORTC Quality of Life Multiple Myeloma Module- 20 items (QLQ-MY20) primary domains

  Time frame: Up to 5 years after the last participant is randomized

• Time to meaningful improvement in EORTC QLQ-C30 global health status/QoL.

  Time frame: Up to 5 years after the last participant is randomized